menu
    • menu
    [{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Levalbuterol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Acquisition","leadProduct":"Levalbuterol Hydrochloride","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Lupin Ltd"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Fahim Khorfan, MD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Levalbuterol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Fahim Khorfan, MD","highestDevelopmentStatusID":"11","companyTruncated":"Ascension Health \/ Fahim Khorfan, MD"}]

    Find Clinical Drug Pipeline Developments & Deals for Levalbuterol Hydrochloride

    Menu

    Levalbuterol Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Levalbuterol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lupin Atlantis Holdings to Acquire Accretive Established Products in Europe and Canada from Sanofi

                            Details : Through th acquisition, Lupin expand its portfolio of accretive established products in Europe and Canada, including Xopenex (levalbuterol HCl), a short-acting β₂ adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulm...

                            Product Name : Xopenex

                            Product Type : HPAPI

                            Upfront Cash : Undisclosed

                            December 23, 2023

                            Lead Product(s) : Levalbuterol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sumitomo Pharma America

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sumitomo Pharma America

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levalbuterol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

                            Details : Levalbuterol is a HPAPI drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            August 03, 2012

                            Lead Product(s) : Levalbuterol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ascension Health

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Ascension Health

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levalbuterol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Fahim Khorfan, MD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Nebulized Bronchodilators on Heart Rate

                            Details : Levalbuterol is a HPAPI drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            June 28, 2010

                            Lead Product(s) : Levalbuterol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Fahim Khorfan, MD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth